Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131 - PubMed (original) (raw)
Multicenter Study
doi: 10.1089/mdr.2014.0261. Epub 2015 Mar 10.
Affiliations
- PMID: 25756854
- DOI: 10.1089/mdr.2014.0261
Multicenter Study
Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131
Sun Young Cho et al. Microb Drug Resist. 2015 Aug.
Abstract
Despite the remarkable emergence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli sequence type 131 (ST131), the clinical features and outcomes of infections caused by ST131 remain poorly described. From 2011 to 2012, we collected ESBL-producing E. coli isolates from patients with bloodstream infections in 13 hospitals in Korea and compared clinical characteristics and outcomes between ST131 and non-ST131 clones. Of the 110 ESBL-producing isolates, the most common ST was ST131 (30.9%). Multivariate analysis showed that recent operation was the only variable associated with the ST131 clone; other comorbid conditions and clinical features were similar between ST131 and non-ST131 clones. CTX-M-14 and CTX-M-15 were the predominant types of ESBLs, and CTX-M-15 was significantly associated with ST131. The rate of nonsusceptibility to ciprofloxacin was higher in ST131 than in non-ST131 clones (94.1% vs. 75.0%). No significant differences in 30-day mortality rates were found between ST131 and non-ST131 clones. Multivariate analysis revealed that older age (odds ratio [OR]=5.39, 95% confidence interval [CI] 1.22-23.89; p=0.027), nosocomial infection (OR=4.81, 95% CI 1.15-20.15; p=0.032), and higher Pitt bacteremia score (OR=7.26, 95% CI 1.41-37.42; p=0.018) were independent risk factors for 30-day mortality. The ESBL-producing E. coli ST131 clone has emerged and disseminated in Korea. Our findings reveal similarities in clinical and demographic characteristics between ST131 and non-ST131 clones. Although a more resistant profile has been detected in ST131, patients with the ST131 clone did not exhibit a higher mortality rate.
Similar articles
- Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality.
Chung HC, Lai CH, Lin JN, Huang CK, Liang SH, Chen WF, Shih YC, Lin HH, Wang JL. Chung HC, et al. Antimicrob Agents Chemother. 2012 Feb;56(2):618-22. doi: 10.1128/AAC.05753-11. Epub 2011 Nov 28. Antimicrob Agents Chemother. 2012. PMID: 22123694 Free PMC article. - Prevalence of CTX-M extended-spectrum beta-lactamases and sequence type 131 in Korean blood, urine, and rectal Escherichia coli isolates.
Graham SE, Zhang L, Ali I, Cho YK, Ismail MD, Carlson HA, Foxman B. Graham SE, et al. Infect Genet Evol. 2016 Jul;41:292-295. doi: 10.1016/j.meegid.2016.04.020. Epub 2016 Apr 19. Infect Genet Evol. 2016. PMID: 27101781 - Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. Ha YE, et al. Int J Antimicrob Agents. 2013 Nov;42(5):403-9. doi: 10.1016/j.ijantimicag.2013.07.018. Epub 2013 Sep 7. Int J Antimicrob Agents. 2013. PMID: 24071027 - Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4.
Peirano G, Pitout JD. Peirano G, et al. Int J Antimicrob Agents. 2010 Apr;35(4):316-21. doi: 10.1016/j.ijantimicag.2009.11.003. Epub 2010 Jan 13. Int J Antimicrob Agents. 2010. PMID: 20060273 Review. - Emergence of Escherichia coli ST131 Causing Urinary Tract Infection in Western Asia: A Systematic Review and Meta-Analysis.
Jafari A, Falahatkar S, Delpasand K, Sabati H, Sedigh Ebrahim-Saraie H. Jafari A, et al. Microb Drug Resist. 2020 Nov;26(11):1357-1364. doi: 10.1089/mdr.2019.0312. Epub 2020 May 7. Microb Drug Resist. 2020. PMID: 32380906
Cited by
- Epidemiology of extended-spectrum β-lactamases in Enterobacterales in Taiwan for over two decades.
Chao CM, Lai CC, Yu WL. Chao CM, et al. Front Microbiol. 2023 Jan 25;13:1060050. doi: 10.3389/fmicb.2022.1060050. eCollection 2022. Front Microbiol. 2023. PMID: 36762100 Free PMC article. Review. - Prevalence and characteristics of ST131-O16 and ST131-O25b clones among extended-spectrum β-lactamase-producing Escherichia coli isolates causing bloodstream infection in Iran.
Ebrahimi MT, Halimi S, Yavari-Bafghi M, Beigverdi R, Rahdar HA, Emaneini M, Jabalameli F. Ebrahimi MT, et al. Mol Biol Rep. 2025 Feb 5;52(1):206. doi: 10.1007/s11033-025-10310-y. Mol Biol Rep. 2025. PMID: 39907737 - The higher prevalence of extended spectrum beta-lactamases among Escherichia coli ST131 in Southeast Asia is driven by expansion of a single, locally prevalent subclone.
Chen SL, Ding Y, Apisarnthanarak A, Kalimuddin S, Archuleta S, Omar SFS, De PP, Koh TH, Chew KL, Atiya N, Suwantarat N, Velayuthan RD, Wong JGX, Lye DC. Chen SL, et al. Sci Rep. 2019 Sep 13;9(1):13245. doi: 10.1038/s41598-019-49467-5. Sci Rep. 2019. PMID: 31519972 Free PMC article. - Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections.
Park SY, Kang CI, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. Park SY, et al. Korean J Intern Med. 2017 Jan;32(1):146-157. doi: 10.3904/kjim.2015.113. Epub 2016 Apr 20. Korean J Intern Med. 2017. PMID: 27093979 Free PMC article. - From Pathophysiological Hypotheses to Case-Control Study Design: Resistance from Antibiotic Exposure in Community-Onset Infections.
Abbara S, Guillemot D, Brun-Buisson C, Watier L. Abbara S, et al. Antibiotics (Basel). 2022 Feb 4;11(2):201. doi: 10.3390/antibiotics11020201. Antibiotics (Basel). 2022. PMID: 35203803 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical